CD40LG and diabetes mellitus: In light of previous publications studying CD40–CD40L inhibition in the same model (54, 60, 94), we administered treatments here from 5 to 18 weeks of age and monitored the diabetes incidence by regular glycemia measurements during an extended follow-up period until the mice reached 40 weeks of age.